エピソード

  • Why Customer Success Is the Next Major Category in MedTech with Rupal Ayer, Senior Director of Customer Success at Solventum

    Why Customer Success Is the Next Major Category in MedTech with Rupal Ayer, Senior Director of Customer Success at Solventum
    2026/07/02
    MedTech companies invest heavily in acquiring customers, but many still lack a clear strategy for retaining, expanding, and learning from them. Fortunately, SaaS and tech already solved this years ago through the creation of a commercial function called Customer Success. In this episode, Rupal Ayer, Senior Director of Customer Success at Solventum, discusses why Customer Success should become a formal business category in healthcare. He explains how combining customer experience with customer outcomes can strengthen retention, guide enterprise decisions, and improve commercial performance. Rupal also shares how Customer Success connects sales, marketing, and service around the customer journey while helping organizations move from transactional vendors to trusted advisors. And building a culture that translates customer reality into enterprise action. Tune in to learn how embedding the voice of the customer at the center of enterprise decision-making can improve business performance and create better experiences for clinicians and patients. Resources: Connect with and follow Rupal Ayer on LinkedIn. Follow Solventum on LinkedIn and explore their website.
    続きを読む 一部表示
    23 分
  • Closing the Treatment Gap for Patients Living with Tremor with Deanna Harshbarger, CEO of Cala Health

    Closing the Treatment Gap for Patients Living with Tremor with Deanna Harshbarger, CEO of Cala Health
    2026/06/30
    Many patients with tremor are caught between medications that lose effectiveness and invasive procedures they may not be ready to pursue. In this episode, Deanna Harshbarger, CEO of Cala Health, discusses how non-invasive bioelectronic medicine is creating a new treatment pathway for patients with essential tremor. She explains how Cala’s wearable therapy measures each patient’s tremor, personalizes stimulation, and uses the peripheral nervous system to interrupt tremor-related signals. Deanna also shares how the company overcame regulatory, reimbursement, and access challenges while building an entirely new category of care. Tune in to learn how patient-centered design, perseverance, and personalized neurostimulation are expanding treatment options for people living with tremor. Resources: Connect with and follow Deanna Harshbarger on LinkedIn. Follow Cala Health on LinkedIn and explore their website. Watch the video to learn how Cala Therapy works: https://calahealth.com/product/how-taps-works/
    続きを読む 一部表示
    17 分
  • Changing the Clinical Value Equation in Orthopedic Care with Nic Aldrich, Vice President of Marketing at OrthAlign

    Changing the Clinical Value Equation in Orthopedic Care with Nic Aldrich, Vice President of Marketing at OrthAlign
    2026/06/25
    Orthopedic procedures are increasingly moving to ambulatory surgery centers, but many navigation technologies remain too expensive, complex, or inefficient for that setting. In this episode, Nic Aldrich, Vice President of Marketing at OrthAlign, discusses how handheld navigation technology is making precision orthopedic care more accessible. He explains how OrthAlign helps surgeons reduce variability, execute patient-specific plans, and bring advanced technology into total hip, knee, partial knee, and revision procedures. Nic also shares how the newly cleared Lantern ASC system was designed specifically for surgery centers, balancing accuracy with cost, speed, and ease of use. Tune in to learn how smaller, more efficient technologies are helping expand access to precision orthopedic care. Resources: Connect with and follow Nic Aldrich on LinkedIn. Follow OrthAlign on LinkedIn and explore their website. Learn more about the Lantern ASC system here.
    続きを読む 一部表示
    16 分
  • Using AI to Strengthen Clinical Confidence in Procedures with Will Mauldin, Co-Founder and CEO of Rivanna Medical

    Using AI to Strengthen Clinical Confidence in Procedures with Will Mauldin, Co-Founder and CEO of Rivanna Medical
    2026/06/23
    AI in medtech is most valuable when it supports better clinical decisions, not when it replaces clinicians. In this episode, Alexis Anderson speaks with Will Mauldin, Co-Founder and CEO of Rivanna Medical, live from DeviceTalks Boston. Will explains how Rivanna is bringing AI-enabled imaging to clinical settings where providers have traditionally relied on blind or manual procedures, beginning with epidural anesthesia guidance and expanding into fracture detection. He shares how the company’s handheld spine guidance technology helps clinicians visualize the epidural space, use AI as a confirmation tool, and build confidence through consistent outcomes. Will also discusses broader medtech trends around AI, automation, connected devices, and robotics, along with funding challenges for mid-stage companies and Rivanna’s upcoming FDA milestones. Tune in and learn how AI-enabled imaging can improve safety, reduce bottlenecks, and support clinicians in high-demand care environments. Resources Connect and follow Will Mauldin on LinkedIn. Follow Rivanna Medical on LinkedIn and explore their website.
    続きを読む 一部表示
    12 分
  • From Blind Biopsies to Precision: Reinventing Medical Imaging with Reza Khorasaninejad, Founder & CEO at LEADOPTIK

    From Blind Biopsies to Precision: Reinventing Medical Imaging with Reza Khorasaninejad, Founder & CEO at LEADOPTIK
    2026/06/22
    Lung cancer biopsies are still being done blind more often than you’d think, leading to costly diagnostic errors. In this episode, Reza Khorasaninejad, Founder & CEO at LEADOPTIK, discusses how advances in photonics and metasurface engineering are enabling highly miniaturized imaging systems for minimally invasive procedures. These innovations aim to address a major challenge in lung cancer biopsies: a lack of imaging guidance that can lead to significant diagnostic errors. Early clinical pilots across multiple sites are demonstrating strong performance, with one hospital already converting into a paying customer. Looking ahead, the company is partnering with Stanford Medicine to develop AI-driven decision support tools to further improve diagnostic accuracy. Tune in to learn how next-generation imaging and AI are changing that reality and helping physicians hit the right target the first time! Resources: Connect with and follow Reza Khorasaninejad on LinkedIn.Follow LEADOPTIK on LinkedIn and explore their website!
    続きを読む 一部表示
    12 分
  • Building Bridges Across the Healthcare Ecosystem with Adam McMullin, CEO of AvaSure

    Building Bridges Across the Healthcare Ecosystem with Adam McMullin, CEO of AvaSure
    2026/06/18
    Healthcare technology only matters when it makes care safer, more accessible, and easier to deliver at scale. In this episode, Adam McMullin, CEO of AvaSure, joins Saul to discuss how virtual care, ambient AI, and smart room platforms are transforming inpatient care. He explains how AvaSure creates a “cocoon of safety” around patients and care teams through capabilities such as fall prevention, violence reduction, and expanded access to specialty care. Adam emphasizes that lasting technology adoption depends on thoughtful clinical workflow design, nurse engagement, open architecture, and strong partner ecosystems. He also shares leadership lessons on values alignment and explains why health systems are increasingly scaling smart room technologies to address financial pressures, workforce shortages, and efficiency demands. Tune in and learn how proven technology, trusted partnerships, and aligned leadership can help health systems deliver safer, smarter care. Resources: Connect with and follow Adam McMullin on LinkedIn. Follow AvaSure on LinkedIn and explore their website!
    続きを読む 一部表示
    16 分
  • Creating the Future of MedTech Through Purpose with James Corbett, transformational MedTech CEO and Board Advisor

    Creating the Future of MedTech Through Purpose with James Corbett, transformational MedTech CEO and Board Advisor
    2026/06/17
    MedTech innovation succeeds when bold ideas are matched with disciplined execution, strong teams, and a clear purpose. In this episode, James Corbett, transformational MedTech CEO and Board Advisor, joins Saul to share the leadership lessons, operating principles, and industry changes that have shaped his decades-long career. Drawing on experience leading companies including Boston Scientific, ev3, Alphatec Spine, CathWorks, and AVITA Medical, Jim explains why people and purpose are the foundation of lasting success in healthcare. He discusses the future of MedTech, including the creation of new clinical categories, the importance of operational excellence, and the growing role of AI in leadership and business transformation. Jim also shares why many organizations are underutilizing AI, how his AI command center captures decades of operating knowledge, and why great people remain the ultimate competitive advantage. Tune in and learn how purpose-driven leadership, operational discipline, and AI-enabled execution can help shape the next generation of MedTech innovation! Resources: Connect with and follow James Corbett on LinkedIn. Explore Jim Corbett AI!
    続きを読む 一部表示
    32 分
  • Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity

    Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity
    2026/06/16
    The future of market access belongs to organizations that plan years in advance. In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed. Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage! Resources: Connect with and follow Steve Mather on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts/
    続きを読む 一部表示
    25 分